Loading
companiesCompany
ImmunoACT
The IIT Bombay spin-off that won India's first CAR-T approval in 2023 with NexCAR19 and has treated more than 600 patients at a tenth of Western prices.
Overview
ImmunoACT was established in 2018 as a spin-off from IIT Bombay, where Rahul Purwar's group had worked on a humanised CD19 CAR since 2013. Clinical development ran with Tata Memorial Centre: first patients were dosed at Tata Memorial Hospital in 2021 and the DCGI granted market authorisation for NexCAR19 (talicabtagene autoleucel) in 2023, India's first approved CAR-T therapy. The phase 1/2 study (64 enrolled at six centres) reported an overall response rate of 73% in 51 evaluable patients. The company reports more than 600 patients treated across over 130 authorised centres, a 98% manufacturing success rate, about 20 days from apheresis to infusion and a WHO-certified GMP facility with capacity for 750 patients a year, expanding to 1,500. It received a US patent in 2025 and in 2026 partnered with Cipla to supply South Africa, Algeria and Morocco.
Headquarters
Mumbai, IN
Scorecard
All companies#338of 1244 companies, score 11
- approved products +6
- targets +2
- modalities +2
- regions +1
1 approved, 0 in phase 3, 0 earlier, 1 targets, 0 registry studies. Formula on the scorecards page.
Type
Website
Founded
2018
ApprovedCAR-T (CD19, humanised)
Talicabtagene autoleucel · NexCAR19
India's first home-grown CAR-T cell therapy, approved in 2023 for relapsed leukaemia and lymphoma, made in Mumbai for roughly a tenth of what the same kind of treatment costs in the US.
Rahul Purwar
Professor, Department of Biosciences and Bioengineering, IIT Bombay; founder, ImmunoACT
CAR-T cell engineeringImmunologyCell therapy manufacturing
The IIT Bombay immunologist whose laboratory designed India's first approved CAR-T therapy and who founded the company that makes it for a fraction of Western prices.
Hasmukh Jain
Professor of Medical Oncology (adult haematolymphoid), Tata Memorial Hospital
LymphomaAcute leukaemiaCAR-T cell therapy
First author of the phase 1/2 trial of India's first CAR-T therapy, which treated adults with relapsed lymphoma and leukaemia at six Indian centres.
Gaurav Narula
Professor of Paediatric Oncology, Tata Memorial Hospital
Paediatric oncologyChildhood leukaemiaCAR-T cell therapy
A paediatric oncologist at Tata Memorial who led the leukaemia arm of India's first CAR-T trials and runs national childhood leukaemia protocols.
Similar pages
- IdeaPublic-sector CAR-T manufacturing in India, Brazil and South Africa under $50,000
Shares Talicabtagene autoleucel, Tata Memorial Centre, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Manufacturing cost and time for living and radioactive medicines.
- TrialIMAGINE (varnimcabtagene autoleucel, Immuneel)
Shares Point-of-care and decentralised cell manufacturing, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Manufacturing cost and time for living and radioactive medicines, CD19.
- TreatmentVarnimcabtagene autoleucel
Shares Point-of-care and decentralised cell manufacturing, Talicabtagene autoleucel, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Manufacturing cost and time for living and radioactive medicines.
- CompanyImmuneel Therapeutics
Shares Point-of-care and decentralised cell manufacturing, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Manufacturing cost and time for living and radioactive medicines, CD19.
- CompanyCellogen Therapeutics
Shares Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
- Key paperUCART19: the first gene-edited, donor-derived CAR-T cells in children and adults with relapsed B-cell ALL
Shares Point-of-care and decentralised cell manufacturing, Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy.
- Key paperA National Cancer Grid pooled procurement initiative, India
Shares Tata Memorial Centre, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Most of the world has almost no cancer care.
- PersonZelig Eshhar
Shares Manufacturing cost and time for living and radioactive medicines, CD19, CAR-T cell therapy, Acute lymphoblastic leukaemia.
cancers
fronts
technologies
targets
drugs
ApprovedCAR-T (CD19, humanised)
Talicabtagene autoleucel · NexCAR19